Before prostate MRI became a routine part of many diagnostic pathways, men with suspected prostate cancer often moved directly from a raised PSA result to biopsy. If you had an elevated PSA level, you may have been referred for a biopsy without having detailed information about whether a significant cancer was likely to be present.
While biopsies helped diagnose prostate cancer, traditional approaches could sometimes miss important tumours or identify cancers that may never have caused problems. This created challenges for doctors and patients when deciding who needed further investigation and treatment.
The PROMIS Trial was one of the landmark studies that changed this approach. It demonstrated the value of multiparametric MRI (mpMRI) in assessing men with suspected prostate cancer and showed that MRI could improve the identification of clinically significant disease.
The study helped change how diagnosis is approached today. Instead of using biopsy as the first major investigation for every patient, your specialist can use MRI findings alongside PSA results and other risk factors to decide whether a biopsy is needed and how it should be targeted.
Why Was the PROMIS Trial Important?
The PROMIS Trial was important because prostate cancer diagnosis has always involved finding the right balance. Your specialist needs to identify cancers that could affect your health while also avoiding unnecessary procedures and treatments when they are unlikely to provide benefit.
Before MRI became widely adopted, many men with raised PSA levels or clinical suspicion of prostate cancer underwent systematic biopsies. If you were in this situation, the biopsy process could sometimes detect cancers that were unlikely to cause harm while also missing some clinically important tumours.
The trial explored whether using MRI before biopsy could make the diagnostic process more accurate and personalised. By providing additional information about your prostate, MRI could help your doctor make better decisions about whether a biopsy was needed and where samples should be taken.
What Was the Aim of the PROMIS Trial?
The main aim of the PROMIS Trial was to assess how accurately multiparametric MRI (mpMRI) could detect clinically significant prostate cancer. If you were being investigated for possible prostate cancer, the study helped explain how MRI could provide additional information before deciding whether a biopsy was needed.
Researchers compared MRI findings with biopsy results to understand how reliable MRI could be as a diagnostic tool. This allowed doctors to assess whether imaging could identify important cancers more effectively than relying only on traditional diagnostic methods.
The study focused on more than simply detecting any cancer cells. It aimed to identify cancers that were more likely to affect your health and require treatment, helping your specialist make more informed decisions about your diagnosis and care.
Who Took Part in the PROMIS Trial?
The PROMIS Trial involved men who had a raised PSA level or other findings that suggested possible prostate cancer. If you had been in a similar situation, you may have faced the same uncertainty about whether further testing was needed and what the most appropriate next step would be.
The men included in the study had not previously undergone a prostate biopsy. This allowed researchers to assess how effectively MRI could be used as an early assessment tool before invasive testing was carried out.
The results provided important evidence about using MRI earlier in the diagnostic pathway rather than only after previous negative biopsies. This helped support a shift towards using your MRI findings, alongside other clinical information, to guide decisions about whether biopsy is necessary.
What Is Multiparametric MRI?
Multiparametric MRI, often shortened to mpMRI, combines several MRI techniques to create detailed images of the prostate. If you are having a prostate MRI as part of your assessment, this scan can provide your specialist with more detailed information about what is happening inside the gland.
Unlike traditional imaging methods, mpMRI provides information about prostate structure, tissue characteristics, and areas that may appear suspicious. This helps doctors identify regions that may need closer examination and assess the likelihood of clinically significant cancer.
By providing a clearer view of your prostate, mpMRI gives specialists additional information when deciding whether further investigation, such as a targeted biopsy, may be required. This makes the diagnostic process more focused and personalised.
How Was Prostate Cancer Diagnosed Before MRI?
Before MRI became widely used, prostate cancer was often diagnosed using ultrasound-guided systematic biopsy. After a raised PSA or other concerns, multiple tissue samples were taken from different areas of the prostate, without knowing exactly where significant cancer might be located.
- Systematic Sampling: Doctors collected samples from across the prostate to detect cancer, even though the exact location of important tumours was not visible.
- Limitations of Ultrasound: Conventional ultrasound did not reliably show which areas were most likely to contain significant cancer, so targeting was less precise.
- Important Diagnostic Role: Despite its limitations, systematic biopsy remained a key method for detecting prostate cancer.
- Transition to MRI-Based Pathways: Modern MRI allows specialists to assess the prostate in detail, helping decide whether a biopsy is needed and where samples should be taken.
Overall, before MRI, prostate biopsies relied on broad sampling rather than targeted detection. MRI now improves precision, helping doctors focus on areas most likely to contain clinically significant cancer.
What Problem Did Traditional Biopsy Have?
One challenge with traditional biopsy was that prostate cancer is not always evenly distributed throughout the prostate gland. If you were undergoing a systematic biopsy, samples were taken from standard areas of the prostate, which meant that an important tumour could sometimes be missed if it was located elsewhere.
A biopsy could fail to detect significant cancer when your samples did not include the area where the tumour was present. This created uncertainty because a negative result did not always mean that clinically important cancer was completely ruled out.
There was also concern that systematic biopsies could identify small, low-risk cancers that might never have caused symptoms during your lifetime. This could lead to additional investigations, anxiety, and difficult decisions about whether treatment was necessary.
What Did the PROMIS Trial Discover?
The PROMIS Trial showed that multiparametric MRI (mpMRI) had a strong ability to identify clinically significant prostate cancer. If you were being investigated for possible prostate cancer, this meant MRI could provide valuable information about the likelihood of important disease before moving forward with an invasive procedure.
The study demonstrated that MRI could improve the diagnostic process by helping your specialist identify areas of concern within the prostate. This additional information allowed doctors to make more informed decisions about whether a biopsy was likely to be beneficial.
The findings supported the idea that MRI should be considered an important step before deciding whether a biopsy is required. By using MRI alongside PSA results and other clinical factors, you can have a more personalised assessment based on your individual risk.
Evidence Note:
The PROMIS Trial evaluated whether multiparametric MRI could accurately identify clinically significant prostate cancer before biopsy. Compared with template mapping biopsy as the reference standard, mpMRI showed high sensitivity for clinically significant disease, detecting 93% of cases with a negative predictive value of 89%.
For comparison, standard TRUS biopsy detected fewer clinically significant cancers in the study population. However, MRI and biopsy serve different purposes: MRI helps identify areas that may require investigation, while biopsy provides tissue confirmation and information about tumour characteristics. For you as a patient, this means MRI can help guide decisions about whether biopsy is needed and where samples should be taken, but it does not replace tissue diagnosis completely.
How Did PROMIS Change the Diagnostic Pathway?
The biggest change from the PROMIS Trial was the move away from a biopsy-first approach towards an MRI-first approach. If you had a raised PSA level, you would no longer necessarily move straight to biopsy without further assessment.
Instead, your specialist can use MRI to assess your individual risk before deciding whether a biopsy is needed. This helps identify suspicious areas within the prostate and provides more information about whether further investigation is likely to be beneficial.
This approach has made prostate cancer diagnosis more personalised and focused. By using your MRI findings alongside PSA levels and other risk factors, doctors can reduce unnecessary procedures for some patients while still identifying cancers that require attention.
Key Impacts of MRI in the PROMIS Trial
| Feature / Outcome | Before MRI (Standard TRUS Biopsy) | After MRI (PROMIS Findings) | Notes |
| Biopsy necessity | All men with elevated PSA underwent systematic biopsy | Some men (with low-risk MRI) avoided biopsy | Reduces unnecessary invasive procedures |
| Detection of clinically significant cancer | 48% sensitivity | 93% sensitivity | Improves identification of cancers needing treatment |
| Detection of clinically insignificant cancer | Higher chance of detecting low-risk cancers | Reduced overdiagnosis | Focus on clinically relevant cancers |
| Personalised assessment | Limited; biopsy taken from standard areas | Targeted biopsy guided by MRI findings | Improves precision and patient involvement |
| Patient experience | Anxiety due to routine biopsy | Fewer unnecessary biopsies; clearer pathway | Reduces procedural burden and potential complications |
Did PROMIS Mean Everyone Could Avoid Biopsy?
No. The PROMIS Trial did not show that prostate biopsy was no longer needed. If you are being assessed for possible prostate cancer, MRI can provide valuable information, but it does not completely replace the need for tissue sampling in every situation.
MRI is an important diagnostic tool, but it cannot always confirm whether cancer is present or determine the exact characteristics of cancer cells. Your specialist will consider your MRI findings alongside your PSA level, symptoms, family history, and other risk factors before recommending the next step.
When your MRI shows suspicious areas, a biopsy is often still required to provide a definitive diagnosis. The biopsy results help your doctor understand whether cancer is present, how aggressive it may be, and what treatment or monitoring approach may be appropriate for you.
Why Is a Biopsy Still Needed?
A biopsy is still needed because it provides tissue samples that can be examined under a microscope. If you are being investigated for possible prostate cancer, the biopsy gives your specialist information that imaging alone cannot provide.
By analysing these tissue samples, doctors can confirm whether cancer cells are present and assess important features such as the grade and aggressiveness of the tumour. This information helps your healthcare team understand how the cancer is likely to behave and what treatment options may be most appropriate for you.
MRI can show where cancer may be located and identify areas that look suspicious, but it cannot provide the detailed cellular information required for a definitive diagnosis. By combining your MRI findings with biopsy results, your specialist can create a more accurate and personalised treatment plan.
Biopsy Safety Note:
A prostate biopsy is generally safe, but it can cause temporary side effects such as blood in the urine, blood in the semen, discomfort, bruising or infection. Serious infection is uncommon but can occur, especially with transrectal biopsy. Your specialist should explain the type of biopsy being recommended, why it is needed, what the risks are and what symptoms should prompt urgent medical advice after the procedure.
What Does Clinically Significant Cancer Mean?
Clinically significant prostate cancer refers to cancers that are more likely to grow, spread, or affect your health over time. If you are being assessed for prostate cancer, understanding this difference is important because not every cancer found within the prostate behaves in the same way.
This is different from simply finding every possible cancer cell within the prostate. Some very small or low-risk cancers may grow slowly and may never cause problems during your lifetime, while others may require closer monitoring or treatment.
Modern diagnosis aims to identify cancers that are more likely to matter to you while avoiding unnecessary diagnosis and treatment of very low-risk disease. By using tools such as MRI, PSA testing, and biopsy results together, your specialist can provide a more personalised assessment of your individual risk.
How Did PROMIS Help Reduce Overdiagnosis?
Overdiagnosis occurs when a test identifies a cancer that may never have caused harm or affected your health during your lifetime. If you are diagnosed with a low-risk cancer that may not have required immediate treatment, it can lead to unnecessary worry, further investigations, and difficult decisions.
Traditional diagnostic approaches could sometimes detect cancers that were unlikely to cause problems while exposing you to additional procedures and potential treatment side effects. This highlighted the need for a more targeted way of identifying which cancers were important to find.
By improving the selection of men who are most likely to benefit from biopsy, MRI-based pathways aim to reduce some unnecessary diagnoses while still detecting clinically significant cancers. This allows your specialist to focus on finding disease that is more likely to affect you and guide treatment decisions appropriately.
How Did PROMIS Influence MRI Before Biopsy?
The PROMIS Trial provided important evidence that MRI could be used before biopsy to assess the likelihood of clinically significant cancer and guide further investigation. If you are being assessed for possible prostate cancer, your diagnostic pathway may now include MRI before deciding whether a biopsy is needed.
Doctors began using MRI findings to assess whether a biopsy was likely to provide useful information. By identifying areas that appear suspicious, your specialist can make a more informed decision about whether tissue sampling is required and how it should be targeted.
This approach improved the order of investigations by making imaging part of the decision-making process rather than simply an additional test. As a result, your assessment can become more personalised, helping to reduce unnecessary procedures while improving the detection of important cancers.
UK Guidance Note:
In UK practice, NICE recommends multiparametric MRI as the first-line investigation for people with suspected clinically localised prostate cancer. NICE also recommends offering MRI-influenced prostate biopsy when the MRI score is 3 or more, and considering whether biopsy can be omitted when the MRI score is 1 or 2 after discussing the risks and benefits with the patient. This means MRI is now central to prostate cancer assessment, but biopsy decisions still depend on PSA, MRI findings, prostate size, examination results, family history and overall risk.
What Happens If MRI Shows a Suspicious Area?
If your MRI identifies an area that appears suspicious, your specialist may recommend a targeted biopsy to investigate it further. This means the biopsy is focused on the specific area that needs closer assessment rather than relying only on samples taken from standard areas of the prostate.
The MRI helps guide your doctor towards the region most likely to contain clinically significant cancer. If you are undergoing this type of biopsy, the imaging information allows your specialist to take samples with a clearer understanding of where an abnormality may be located.
This targeted approach can improve the chance of obtaining useful tissue samples compared with traditional random sampling methods. By combining your MRI findings with biopsy results, your healthcare team can gain a more accurate understanding of your prostate health and guide the next steps in your care.
What Happens If MRI Looks Normal?
A normal or low-suspicion MRI result can be reassuring for many men. If you receive this type of result, it may suggest that clinically significant prostate cancer is less likely, but it does not completely rule out the possibility of cancer.
Your MRI findings will always be interpreted alongside other important information, including your PSA level, prostate size, family history, examination findings, and overall risk factors. This helps your specialist understand your individual situation rather than relying on the scan result alone.
Depending on your circumstances, your doctor may recommend monitoring, repeat PSA testing, or further assessment. By considering your complete clinical picture, your specialist can help decide the most appropriate next step for you.
Clinical Tip: A Normal MRI Is Reassuring, Not Absolute
A normal or low-suspicion MRI can reduce the chance of clinically significant prostate cancer, but it cannot rule it out completely. Your specialist may still recommend monitoring, repeat PSA testing, PSA density assessment or biopsy if your overall risk remains concerning. This is why MRI results should always be interpreted alongside your PSA level, age, prostate size, family history and examination findings.
How Did PROMIS Affect Patient Experience?
Before MRI became widely used in prostate cancer assessment, many men faced uncertainty after a raised PSA result because biopsy was often the next immediate step. If you received an abnormal PSA result, you may have felt unsure about whether an invasive procedure was necessary or what the results might show.
The PROMIS Trial helped introduce a more structured pathway where MRI could provide additional information before deciding on further testing. This allows your specialist to better explain whether a biopsy is recommended and why it may be useful in your individual situation.
For many patients, this means having a clearer understanding of the diagnostic process. When you know how MRI findings, PSA levels, and other risk factors influence decisions, you can feel more involved and confident when discussing the next steps in your care.
Can MRI Replace PSA Testing?
No. MRI does not replace the PSA blood test. If you are being assessed for possible prostate cancer, your PSA level remains an important part of the overall diagnostic process, but it is only one piece of the information your specialist will consider.
PSA can provide useful guidance, but it has limitations because your level may be raised for several reasons other than cancer, including prostate enlargement or inflammation. This means a higher PSA result does not always confirm that cancer is present.
MRI adds another layer of information by showing detailed changes within your prostate and helping your doctor assess your individual risk more accurately. By combining your PSA results with MRI findings and other clinical factors, your specialist can make a more informed decision about whether further investigation is needed.
Does MRI Replace Other Prostate Assessments?
MRI has improved prostate cancer assessment, but it has not completely replaced other parts of the diagnostic process. If you are being assessed for possible prostate cancer, your doctor may still consider several factors, including your symptoms, examination findings, PSA results, and overall health.
A digital rectal examination can provide additional information about the prostate, such as changes in size, shape, or texture. While MRI offers detailed images of the prostate, your specialist will use all available information to build a clearer picture of your individual situation.
Prostate cancer diagnosis works best when different pieces of information are combined rather than relying on a single test. By considering your MRI results alongside other clinical factors, your healthcare team can make more accurate and personalised decisions about your care.
How Does MRI Help Doctors Decide About Biopsy?
MRI helps doctors identify areas of the prostate that may require closer examination. If you are being assessed for possible prostate cancer, your MRI results can provide important information about whether a biopsy is likely to be useful and where samples should be taken.
If suspicious areas are seen on your scan, your specialist can use the MRI findings to guide a targeted biopsy towards those specific locations. This increases the chance of collecting tissue from areas that are more likely to contain clinically significant cancer.
If your MRI result is reassuring, your doctor may consider whether an immediate biopsy is necessary based on your overall risk profile. Your PSA level, prostate size, family history, symptoms, and other factors will all help determine the most appropriate next step for you.
What Is MRI-Targeted Biopsy?
MRI-targeted biopsy uses information from your MRI scan to guide where tissue samples should be taken from the prostate. If you are undergoing this type of biopsy, your specialist can use the scan findings to focus on areas that appear more suspicious rather than relying only on standard sampling methods.
Instead of taking samples only from predetermined areas, doctors can target specific regions that may contain clinically significant cancer. This approach aims to improve the accuracy of diagnosis and increase the chance of detecting cancers that are more likely to affect your health.
The PRECISION Trial later reinforced the value of MRI-based pathways by showing that MRI-targeted approaches could improve the detection of clinically significant prostate cancer compared with standard biopsy methods. This has helped make diagnosis more personalised, allowing your healthcare team to use imaging information when planning your investigation.
What Is the Difference Between PROMIS and PRECISION?
The PROMIS Trial and the PRECISION Trial both played important roles in changing how prostate cancer is diagnosed, but they focused on different questions. If you are learning about modern prostate assessment, understanding the difference between these studies can help explain why MRI is now such an important part of the diagnostic pathway.
The PROMIS Trial focused on how accurately multiparametric MRI (mpMRI) could detect clinically significant prostate cancer. It helped show the potential value of using MRI before biopsy by comparing MRI findings with biopsy results and assessing how well imaging could identify important disease.
The PROMIS and PRECISION Trials answered different but related questions. PROMIS investigated the diagnostic accuracy of multiparametric MRI by comparing MRI findings with biopsy methods. It showed that MRI could identify men who were more or less likely to have clinically significant prostate cancer.
PRECISION then tested an MRI-based diagnostic pathway in biopsy-naive men. It showed that using MRI information before biopsy could improve detection of clinically significant cancer while reducing the diagnosis of some clinically insignificant cancers. Together, these studies helped provide the evidence behind modern MRI-informed prostate cancer assessment.
Why Were Both Trials Important?
One study alone rarely changes medical practice completely. If you are trying to understand why MRI is now widely used in prostate cancer assessment, it helps to look at how both the PROMIS and PRECISION Trials contributed different pieces of evidence.
The PROMIS Trial provided evidence that multiparametric MRI was a powerful diagnostic tool for identifying clinically significant prostate cancer. It showed your specialist that MRI could provide valuable information before biopsy and help assess the likelihood of important disease.
The PRECISION Trial demonstrated how an MRI-based approach could be incorporated into a practical diagnostic pathway. Together, these studies helped establish MRI as a central part of modern prostate cancer assessment, allowing your healthcare team to make more informed decisions about biopsy and further management.
What Does This Mean If You Need a Prostate MRI?
If your doctor recommends a prostate MRI, it does not necessarily mean that you have been diagnosed with cancer. If you are being referred for an MRI, the purpose is usually to gather more information about your prostate and help your specialist decide what steps may be needed next.
A prostate MRI provides detailed images that can show areas of concern and help assess whether further investigation, such as a biopsy, may be appropriate. The scan is an important part of the assessment process, but it is only one factor used when making decisions about your care.
Many men have prostate MRI scans after a raised PSA result or other concerns. Having an MRI allows your healthcare team to better understand your individual situation and recommend the most appropriate next step for you.
What Should You Expect from a Prostate MRI Scan?
A prostate MRI is a non-invasive imaging test that creates detailed pictures of your prostate. If you are having an MRI scan, it is usually performed to provide your specialist with more information about your prostate and help guide decisions about whether further investigation is needed.
During the scan, you will usually lie still inside the MRI scanner while images are taken. The process does not involve surgery or tissue sampling, although you may need to follow specific preparation instructions provided by your imaging team before the appointment.
The experience can vary between patients, but your imaging team will explain what will happen and answer any questions you may have before the scan. Understanding the process in advance can help you feel more comfortable and prepared for your MRI appointment.
Why MRI Quality Matters
The usefulness of a prostate MRI depends on the quality of the images produced and the experience of the specialist interpreting them. If you are having an MRI as part of your prostate assessment, the accuracy of the results can be influenced by both the scanning process and the expertise of the reporting team.
A high-quality scan allows your specialist to identify suspicious areas more confidently and provide a clearer assessment of your prostate. This information can help guide decisions about whether a biopsy or further investigation may be appropriate.
Your MRI results should always be reviewed alongside your PSA level, clinical history, examination findings, and other diagnostic information. By considering the complete picture, your healthcare team can make a more accurate and personalised recommendation for you.
What Are the Limitations of MRI?
Although MRI has transformed prostate cancer diagnosis, it is not a perfect test. If you are having a prostate MRI, it is important to understand that the scan provides valuable information but cannot detect every cancer with complete certainty.
Some cancers may not be clearly visible on MRI, while some areas that appear suspicious may turn out not to contain cancer after biopsy. This means your MRI result must be interpreted carefully and considered alongside other clinical information.
Your specialist will combine your MRI findings with other factors, such as your PSA level, examination results, family history, and biopsy findings where appropriate. By looking at the complete picture rather than relying on imaging alone, your healthcare team can make more accurate decisions about your diagnosis and care.
How Has MRI Changed the Role of Biopsy?
Before MRI became a common part of prostate cancer assessment, biopsy was often the main diagnostic step after there was suspicion of cancer. If you had a raised PSA level or other concerns, you may have moved directly towards biopsy without having detailed information about where a possible tumour might be located.
Today, MRI helps your specialist decide whether a biopsy is needed and identifies areas that may require closer investigation. This allows doctors to use imaging information to guide where tissue samples should be taken and improve the accuracy of the diagnostic process.
This has changed biopsy from a broad sampling procedure into a more targeted investigation. By combining your MRI findings with biopsy results, PSA levels, and other risk factors, your healthcare team can create a clearer understanding of your prostate health.
What Does This Mean for Men with Raised PSA?
A raised PSA result can create anxiety because many men immediately worry that cancer may be present. If you receive an elevated PSA result, it is important to understand that this does not automatically mean you have prostate cancer, as PSA levels can increase for several reasons.
The PROMIS Trial showed that modern prostate cancer diagnosis involves more than simply moving from PSA testing directly to biopsy. Your specialist can now use MRI alongside your PSA level and other clinical information to build a clearer picture of your individual risk.
This more personalised approach helps your doctor decide whether further investigation, such as a biopsy, is likely to be beneficial. By understanding your results in context, you can have a more informed discussion about the next steps in your care.
Moving Forward After the PROMIS Trial
The PROMIS Trial changed prostate cancer diagnosis by demonstrating that multiparametric MRI (mpMRI) could provide valuable information before biopsy. If you are being assessed for possible prostate cancer, MRI can now help your specialist understand your individual risk before deciding whether further investigation is needed.
The study helped move prostate cancer assessment towards a more accurate, targeted, and patient-focused approach. Instead of relying only on biopsy results, your doctor can combine MRI findings with PSA levels and other clinical information to make more informed decisions.
If you are considering specialist assessment through a prostate MRI scan in London, your consultation should include a discussion about why MRI has been recommended and how the results may influence your next steps. Understanding the purpose of the scan can help you feel more involved in decisions about your care.
The main lesson from PROMIS is that better diagnosis is not only about finding more cancer. It is about identifying the cancers that are more likely to affect you while reducing unnecessary procedures wherever possible.
Myth vs Fact:
| Myth | Fact |
| PROMIS proved biopsy is no longer needed. | PROMIS showed MRI can improve assessment before biopsy, but biopsy is still needed in many cases. |
| A normal MRI rules out prostate cancer completely. | A normal MRI lowers the chance of significant cancer but does not remove the risk entirely. |
| MRI replaces PSA testing. | PSA remains part of the overall assessment and is interpreted alongside MRI and other risk factors. |
| MRI-targeted biopsy finds every cancer. | Targeting improves accuracy, but no diagnostic test is perfect. |
| PROMIS and PRECISION were the same trial. | PROMIS studied MRI accuracy, while PRECISION tested an MRI-based biopsy pathway. |
| Any prostate cancer found must be treated immediately. | Some low-risk cancers may be monitored carefully rather than treated straight away. |
Key Takeaways:
- The PROMIS Trial showed that multiparametric MRI can improve prostate cancer assessment before biopsy.
- mpMRI had high sensitivity for clinically significant prostate cancer in the PROMIS study.
- A reassuring MRI can reduce the likelihood of significant cancer, but it does not rule it out completely.
- PROMIS provided evidence supporting the use of MRI before biopsy in prostate cancer assessment.
- Biopsy is still needed when tissue diagnosis will affect treatment or monitoring decisions.
- PROMIS focused on MRI accuracy, while PRECISION later tested MRI-targeted biopsy pathways in practice.
- Modern prostate cancer assessment should combine PSA, MRI, biopsy results, prostate size, family history and clinical judgement.
FAQs:
1. What was the main purpose of the PROMIS Trial?
The PROMIS Trial aimed to understand how accurately multiparametric MRI (mpMRI) could detect clinically significant prostate cancer before a biopsy. The study compared MRI findings with biopsy results to see whether MRI could improve the diagnostic process. Its findings helped support the use of MRI as an important step before deciding whether a biopsy is needed.
2. Why was the PROMIS Trial important for prostate cancer diagnosis?
The trial was important because it showed that MRI could provide more detailed information before men underwent a biopsy. This provided evidence supporting MRI-informed assessment before biopsy and helped move diagnosis towards a more informed MRI-based pathway. The aim was to improve cancer detection while reducing unnecessary procedures.
3. What did the PROMIS Trial show about prostate MRI accuracy?
The PROMIS Trial showed that multiparametric MRI could identify many cases of clinically significant prostate cancer more effectively than traditional assessment methods alone. It demonstrated that MRI could help doctors assess which areas of the prostate may need further investigation. However, MRI is still used alongside other tests rather than as a complete replacement for biopsy.
4. Does a prostate MRI mean you can avoid having a biopsy?
In some cases, a reassuring MRI result may allow your specialist to consider omitting or deferring biopsy after reviewing PSA density, clinical findings and overall risk. However, MRI cannot confirm cancer on its own, and a biopsy may still be needed if there are suspicious findings or other risk factors. Your doctor will consider your MRI results, PSA level and overall health before recommending the next step.
5. What is multiparametric MRI (mpMRI) of the prostate?
Multiparametric MRI combines different MRI techniques to create detailed images of the prostate. It provides information about prostate structure and tissue characteristics, helping specialists identify areas that may appear suspicious. This allows doctors to make more informed decisions about whether further investigations are required.
6. How did the PROMIS Trial change the prostate cancer diagnostic pathway?
Before MRI became widely used, many men with a raised PSA level moved directly to a systematic biopsy. The PROMIS Trial supported using MRI earlier in the process to assess risk before deciding whether biopsy was necessary. This created a more personalised approach based on individual results rather than following the same pathway for everyone.
7. Can a normal prostate MRI rule out prostate cancer?
A normal MRI can reduce the likelihood of clinically significant prostate cancer, but it cannot completely exclude the possibility. Your specialist will also consider other factors, including PSA levels, family history, examination findings and symptoms. Depending on your risk profile, monitoring or further investigation may still be recommended.
8. What happens if a prostate MRI shows a suspicious area?
If your MRI identifies a suspicious area, your specialist may recommend an MRI-targeted biopsy to examine it more closely. The scan helps guide doctors towards the area most likely to contain significant cancer. This targeted approach can provide more targeted information than systematic sampling alone.
9. What is the difference between the PROMIS Trial and the PRECISION Trial?
The PROMIS Trial focused on showing how accurately MRI could detect clinically significant prostate cancer before biopsy. The PRECISION Trial looked at how an MRI-based diagnostic pathway could work in practice by comparing MRI-targeted approaches with traditional biopsy methods. Together, both trials helped establish MRI as an important part of modern prostate cancer assessment.
10. What does the PROMIS Trial mean if you have a raised PSA level?
A raised PSA level does not always mean you have prostate cancer, as other conditions can also increase PSA levels. The PROMIS Trial showed that MRI can provide additional information before deciding whether a biopsy is needed. This allows your specialist to assess your individual risk and recommend the most appropriate next step for your situation.
Final Thoughts: How the PROMIS Trial Changed the Future of Prostate Cancer Diagnosis
The PROMIS Trial played an important role in changing how doctors assess men with suspected prostate cancer. By showing that multiparametric MRI could identify men who were more or less likely to have clinically significant disease, the study provided important evidence for using MRI before deciding whether biopsy is needed.
MRI does not replace PSA testing, clinical assessment or biopsy, but it helps your healthcare team make more informed decisions about investigation. When MRI findings are combined with PSA levels, PSA density, examination findings and other risk factors, diagnosis can become more personalised.
If you are considering a prostate MRI scan in London, you can contact us at Prostate Clinic London to discuss your assessment options and understand how MRI may form part of your diagnostic pathway.
References:
- Ahmed, H.U., El-Shater Bosaily, A., Brown, L.C., Gabe, R., Kaplan, R., Parmar, M.K.B., Collaco-Moraes, Y., Ward, K., Hindley, R.G., Freeman, A. et al. (2017) ‘Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study’, The Lancet, 389(10071), pp.815–822. Available at: https://pubmed.ncbi.nlm.nih.gov/28110982/
- Kasivisvanathan, V., Rannikko, A.S., Borghi, M., Panebianco, V., Mynderse, L.A., Vaarala, M.H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R.G. et al. (2018) ‘MRI-targeted or standard biopsy for prostate-cancer diagnosis’, The New England Journal of Medicine, 378(19), pp.1767–1777. Available at: https://pubmed.ncbi.nlm.nih.gov/29552975/
- National Institute for Health and Care Excellence (NICE) (2019, last updated 2021; reviewed 2025) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- Drost, F.J.H., Osses, D.F., Nieboer, D., Bangma, C.H., Steyerberg, E.W., Roobol, M.J. and Schoots, I.G. (2020) ‘Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis’, European Urology, 77(1), pp.78–94. Available at: https://pubmed.ncbi.nlm.nih.gov/31326219/
- Turkbey, B., Rosenkrantz, A.B., Haider, M.A., Padhani, A.R., Villeirs, G., Macura, K.J., Tempany, C.M., Choyke, P.L. et al. (2019) ‘Prostate Imaging Reporting and Data System Version 2.1’, European Urology, 76(3), pp.340–351. Available at: https://pubmed.ncbi.nlm.nih.gov/30898406/